Karolinska Development AB (publ) (KDEVF)
Karolinska Development AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Solna, SE. The stock last traded at $0.26, up 0.00% on the session, giving a market capitalisation of $68.9M. On trailing twelve-month figures it carries a trailing P/E of -0.35, a net margin of -7797.2%. Its beta of 0.24 implies it has historically moved less than the broad market.
Karolinska Development AB (publ) operates as a venture capital firm, primarily focused on providing funding to nascent companies across seed, early, and growth stages. Its investment strategy targets a wide array of life science domains, including pharmaceutical and genetic research and development, medical advancements, healthcare technology, innovative drug delivery systems, biotechnology, and specialized tools and service providers for the life science industry. The company strategically prioritizes investment opportunities within the Nordic region, specifically highlighting Sweden, Iceland, Norway, Finland, and Denmark. While the firm prefers to assume the role of a lead investor in its portfolio enterprises, it also remains open to participating in co-investment ventures. On an annual basis, it endeavors to finance a maximum of five new projects. Karolinska Development AB (publ) was established in 2003 and maintains its headquarters in Stockholm, Sweden.
Karolinska Development AB (publ) is most often compared with the following Healthcare names: